Berberine für Gut Dysbiosis
DPreclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dberberine\u0026condition\u003Dgut\u002Ddysbiosis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
Fazit
Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
Key Study Findings
In Vitro
Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal …
Dose: None
vs.: Sulfasalazine; DSS-induced UC mice
Outcome: UC treatment efficacy
Wirkung: Colon length 1.2x longer than sulfasalazine
None
Population: DSS-induced UC murine model
Review
Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.
Dose: None
vs.: None
Outcome: None
Wirkung: None
None
Population: None
Review
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Dose: None
vs.: None
Outcome: None
Wirkung: None
None
Population: None
Review
Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver …
Dose: None
vs.: None
Outcome: None
Wirkung: None
None
Population: None
Other
Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles.
Dose: None
vs.: Free berberine; DSS-induced UC model vs normal mice
Outcome: DAI scores, inflammatory cytokines, gut microbiota
Wirkung: None
<0.01 (DAI); <0.05 (cytokines)
Population: DSS-induced UC mouse model (male KM mice)
Other
Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis.
Dose: None
vs.: DSS-induced colitis + periodontitis mouse models
Outcome: Periodontal destruction and myeloid cell generation
Wirkung: None
None
Population: DSS-induced colitis with periodontitis mouse model
Key Statistics
2
Studien
100
Teilnehmer
↑
Positive
D
Bewertung
Referenced Papers
International journal of …
2025
15 Zitierungen
Colloids and surfaces. …
2025
11 Zitierungen
Pharmaceuticals (Basel, Switzerland)
2025
8 Zitierungen
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Review
Pharmaceuticals (Basel, Switzerland)
2025
8 Zitierungen
Inflammatory bowel diseases
2025
2 Zitierungen
Pharmaceutics
2025
2 Zitierungen
Phytomedicine : international …
2025
2 Zitierungen
The Journal of …
2025
1 Zitierungen
European journal of …
2025
Archives of oral …
2025
Frontiers in nutrition
2025
Biomedicine & pharmacotherapy …
2024
17 Zitierungen
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
Systematic Review
International journal of …
2024
14 Zitierungen
Frontiers in pharmacology
2024
9 Zitierungen
Hepatology communications
2024
9 Zitierungen
Frontiers in microbiology
2024
6 Zitierungen
Frontiers in microbiology
2024
5 Zitierungen
Indian journal of …
2024
2 Zitierungen
Gut microbes
2023
108 Zitierungen
Biomedicine & pharmacotherapy …
2023
61 Zitierungen
International journal of …
2023
48 Zitierungen
Journal of ethnopharmacology
2023
29 Zitierungen
Frontiers in pharmacology
2023
20 Zitierungen
International journal of …
2023
18 Zitierungen
Current pharmaceutical design
2023
10 Zitierungen
Journal of oral …
2023
10 Zitierungen
Journal of neurogastroenterology …
2023
4 Zitierungen
Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome.
Review
Clinical and experimental …
2023
2 Zitierungen
Microorganisms
2022
212 Zitierungen
Food & function
2022
83 Zitierungen
Phytomedicine : international …
2022
67 Zitierungen
Biomaterials science
2022
34 Zitierungen
Microbiology spectrum
2022
25 Zitierungen
Brazilian journal of …
2022
12 Zitierungen
Pharmacological research
2021
186 Zitierungen
Pharmacological research
2021
147 Zitierungen
Acta pharmacologica Sinica
2021
63 Zitierungen
Frontiers in pharmacology
2021
42 Zitierungen
Frontiers in immunology
2021
22 Zitierungen
Comprehensive Physiology
2021
21 Zitierungen
International journal of …
2021
20 Zitierungen
Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases.
Review
Pharmacological research
2020
65 Zitierungen
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Systematic Review
Journal of integrative …
2020
33 Zitierungen
Pharmacological research
2019
166 Zitierungen
American journal of …
2019
117 Zitierungen
Biomedicine & pharmacotherapy …
2019
72 Zitierungen
Scientific reports
2019
51 Zitierungen
Pharmacological research
2019
31 Zitierungen
Science China. Life …
2018
17 Zitierungen
Alternative therapies in …
2017
9 Zitierungen
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Übliche Dosierungen
- general:
- 500-1,500 mg/day in divided doses
- siboprotocol:
- 500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
- giantimicrobial:
- 500 mg twice daily
Obergrenze: Generally well-tolerated up to 1,500 mg/day in divided doses
In der Forschung untersuchte Dosierungen
| Dosierung | Dauer | Wirkung | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | 6 weeks | Positive | -- |
Beste Einnahmezeit: With meals; divide doses throughout the day (do not take full daily dose at once)
Safety & Side Effects
Gemeldete Nebenwirkungen
- ⚠ GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
- ⚠ May cause uterine contractions (contraindicated in pregnancy)
- ⚠ Headache
- ⚠ Skin rash (rare)
Bekannte Wechselwirkungen
- ● Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
- ● Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
- ● Anticoagulants (may have additive blood-thinning effects)
- ● Metformin (additive glucose-lowering effect; monitor closely)
- ● Macrolide antibiotics (berberine inhibits CYP3A4)
Tolerierbare Höchstaufnahmemenge: Generally well-tolerated up to 1,500 mg/day in divided doses
Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.
Frequently Asked Questions
Does Berberine help with Gut Dysbiosis?
Based on 2 studies with 100 participants, there is preliminary evidence that needs more research that Berberine may support Gut Dysbiosis management. Our evidence grade is D (Very Early Research).
How much Berberine should I take for Gut Dysbiosis?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and Gut Dysbiosis?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 100 total participants. The overall direction of effect is positive.
Related Evidence
Andere Inhaltsstoffe für Gut Dysbiosis
Berberine für andere Beschwerden
FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.